Stock Watch: Investors Baulk At AstraZeneca And Bayer Q3 Updates
China, Generic Competition And Future Profitability Drag On Sentiment
The end of third-quarter earnings season for big pharma brought a muted investor response to AstraZeneca’s results, but a Bayer’s announcement served as a reminder that there is always someone worse off.
